A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial of Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma Who Are Ineligible for Cisplatin Chemotherapy
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Bemcentinib (Primary) ; Nimotuzumab
- Indications Carcinoma; Head and neck cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Mar 2026 New trial record